Becton, Dickinson and Company (BDX) — Fair Value Analysis

Base-case fair value (P50): $120.43 · Current price: $143.47 · Verdict: Overvalued

The Verdict on BDX

Becton Dickinson (BDX), a key player in the Healthcare sector, appears overvalued according to recent Monte Carlo simulations. The current market price of $148.68 significantly exceeds its median fair value (P50) of $123.32. This implies a substantial -17.1% downside potential to reach its estimated fair value, suggesting investors are currently paying a premium for the shares.

How BDX stacks up against Healthcare

The Monte Carlo analysis positions BDX as overvalued at its current $148.68 price, diverging sharply from its $123.32 median fair value. While BDX operates in the Healthcare sector, its operational and financial health are deemed "average" relative to its industry peers. This average quality tier, coupled with a notable -17.1% gap between the current price and P50, indicates that the market's enthusiasm for BDX may not be fully supported by its intrinsic valuation based on simulated outcomes.

What this means for investors

For investors considering BDX, the current valuation suggests caution. The $148.68 share price is considerably higher than the $123.32 P50 fair value, signaling a -17.1% discrepancy that merits attention. Given BDX's "average" quality tier within the Healthcare sector, the current premium appears stretched against its fundamental profile. FairCurve's Monte Carlo simulations provide this clear "overvalued" verdict, guiding investors away from potentially overpaying. Sign up for a free FairCurve account to see the full bear/bull distribution and track BDX's fair value as new fundamentals are released.